Researchers have discovered a new mechanism that is used by a male sex hormone essential for muscle and bone function. The findings could lead to the development of new drugs with fewer side effects, ...

A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

Breast cancers at all stages are defined by the structure of their genomes, researchers find. Targeting these processes early is likely to offer unexpected therapeutic avenues.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

It’s important to note that researchers are likely at least 10 to 30 years away from creating mirror bacteria. On the timescale of a fast-moving field like synthetic biology, a decade is a very long ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...